Stay Up to Date
Breaking News,
Updates, & More
Click Here to

TOP - October 2011 Vol 4, No 7

TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in In the News

The antibody-guided drug conjugate trastuzumab emtansine (T-DM1) as initial therapy prolonged progression-free survival (PFS) for patients with HER2+ metastatic breast cancer compared with docetaxel plus trastuzumab, according to trial results reported at the European Multidisciplinary Cancer Conference.

The conjugate delivers trastuzumab directly to tumor cells by attaching the drug to DM1 using a stable linker. This limits the drug’s exposure to normal cells, thus producing fewer side effects than the drug delivers through traditional means.

TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in In the News

For women with advanced breast cancer resistant to hormonal therapy, combining everolimus and exemestane improves progression-free survival (PFS) by nearly 7 months compared with exemestane alone, according to phase 3 trial results reported at the European Multi - disciplinary Cancer Conference. The Breast Cancer Trials of Oral Everolimus (BOLERO) randomized 724 patients in 24 countries who had been treated previously with letrozole or anastrozole. Previous therapy also included tamoxifen, fulvestrant, and chemotherapy.

TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in In the News

Prostate-specific antigen (PSA)-based screening has not been shown to reduce prostate cancer–specific mortality, but is associated with harms related to subsequent evaluation and treatments, some of which may be unnecessary, according to a new analysis of the evidence by the US Preventive Services Task Force (USPSTF) published online in the Annals of Internal Medicine.

WASHINGTON, DC—Genetic differences among African-American and white men seem to be root causes of the prostate cancer disparities between the 2 groups, according to new data. Prostate cancer is the second most common cancer among men in the United States, with occurrences and mortality rates higher in African- American men compared with white men. Studies show that prostate cancer is a disease conferred by multiple gene mutations, numerous alterations in gene expression, and changes in genome composition.

TOP - October 2011 Vol 4, No 7 published on October 20, 2011
Oral chemotherapeutic agents have transformed the management of cancer treatment— transitioning the primary location of care to the ambulatory setting and providing patients with a convenient, noninvasive option to manage their malignancy.
TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in Breast Cancer
Bevacizumab (Avastin; Genentech) for metastatic breast cancer may be one of the most widely debated, media-reported, and editorialized agents in oncology.
WASHINGTON, DC—The overall incidence of breast cancer is generally higher among white women than black women. The incidence of a second breast cancer in the opposite breast, however, is higher among black women, according to new data.

SAN FRANCISCO—A number of interventions can help reduce breast cancer among women at high risk, but uptake is sluggish, and there can be confusion about which agent to prescribe to a given patient. Seema Khan, MD, professor of surgery at Northwestern University Feinberg School of Medicine, Chicago, addressed the topic of pharmacologic risk reduction at the 2011 Breast Cancer Symposium.

Page 2 of 2
Results 11 - 18 of 18